My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 10 610 / https://doi.org/10.3332/ecancer.2016.610

Clinical Study

Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent

Diclofenac (DCF) is a well-known and widely used non-steroidal anti-inflammatory drug (NSAID), with a range of actions which are of interest in an oncological context. While there has long been an interest in the use of NSAIDs in chemoprevention, there is now emerging evidence that such drugs may have activity in a treatment setting. DCF, which is a potent inhibitor of COX-2 and prostaglandin E2 synthesis, displays a range of effects on the immune system, the angiogenic cascade, chemo- and radio-sensitivity and tumour metabolism. Both pre-clinical and clinical evidence of these effects, in multiple cancer types, is assessed and summarised and relevant mechanisms of action outlined. Based on this evidence the case is made for further clinical investigation of the anticancer effects of DCF, particularly in combination with other agents - with a range of possible multi-drug and multi-modality combinations outlined in the supplementary materials accompanying the main paper.

Keywords: Drug repurposing, diclofenac, NSAID, perioperative intervention, ReDO project

Loading Article Metrics ... Please wait

Related articles

Conference Report: Highlights from the WIN 2017 Symposium, 26–27 June 2017, Paris, France: ‘Expediting Global Innovation in Precision Cancer Medicine’

Abstract | Full Article | PDF Published: 27 Sep 2017 / https://doi.org/10.3332/ecancer.2017.770

Clinical Study: Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer

Abstract | Full Article | PDF Published: 11 Sep 2017 / https://doi.org/10.3332/ecancer.2017.767

Short Communication: The cost of cancer treatment in Portugal

Abstract | Full Article | PDF | Portuguese Published: 06 Sep 2017 / https://doi.org/10.3332/ecancer.2017.765

Short Communication: Systemic anticancer therapy (SACT) for lung cancer and its potential for interactions with other medicines

Abstract | Full Article | PDF Published: 04 Sep 2017 / https://doi.org/10.3332/ecancer.2017.764

Special Issue: The past and future of breast cancer treatment—from the papyrus to individualised treatment approaches

Abstract | Full Article | PDF Published: 08 Jun 2017 / https://doi.org/10.3332/ecancer.2017.746



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence